for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sienna Biopharmaceuticals Inc

SNNA.OQ

Latest Trade

0.21USD

Change

-0.02(-7.87%)

Volume

506,554

Today's Range

0.21

 - 

0.23

52 Week Range

0.10

 - 

5.86

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.23
Open
0.22
Volume
506,554
3M AVG Volume
116.13
Today's High
0.23
Today's Low
0.21
52 Week High
5.86
52 Week Low
0.10
Shares Out (MIL)
30.91
Market Cap (MIL)
6.77
Forward P/E
-0.06
Dividend (Yield %)
--

Latest Developments

More

Sienna Biopharmaceuticals Announces Court Approval Of Chapter 11 Bidding Procedures

Sienna Biopharma Announces Successful Appeal Of Nasdaq Delisting Notice

Sienna Biopharmaceuticals Files 510(K) Submission With FDA For SNA-001, Its Novel Silver Photoparticle Technology To Remove Light Hair

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sienna Biopharmaceuticals Inc

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. It's SNA-120 is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase IIb clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself. It's SNA-125 is a topical Janus kinase 3 (JAK3)/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and pruritus. Nonclinical studies have demonstrated anti-inflammatory activity in an animal model, and a favorable safety profile.

Industry

Biotechnology & Drugs

Contact Info

30699 Russell Ranch Rd Ste 140

+1.818.6292256

https://siennabio.com/

Executive Leadership

Keith R. Leonard

Chairman of the Board

Frederick C. Beddingfield

President, Chief Executive Officer, Director

Alexander Azoy

Chief Financial Officer

Sean Andrews

Vice President, Investor Relations

Kristina M. Burow

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-5.190

2018

-3.590

2019(E)

-3.500
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-62.67
Return on Equity (TTM)
-57.04

Latest News

Latest News

Sienna Biopharma sinks after acne treatment fails two trials

Sienna Biopharmaceuticals Inc said its lead experimental acne treatment failed to meet the main goals of two pivotal trials and that the chances of it clearing a third study appeared weaker, sending its shares tumbling 19 percent.

CORRECTED-UPDATE 1-Sienna Biopharma sinks after acne drug fails two trials

Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its lead experimental treatment for acne did not meet their main goals, sending its shares tumbling nearly 28 percent before the bell.

Sienna Biopharmaceuticals' acne drug fails two trials

Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its acne treatment did not meet their main goals of reducing inflammatory lesions on patients' skin.

BRIEF-Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma

* SEBACIA - ANNOUNCES FAVORABLE RULING BY U.S. FEDERAL COURT REGARDING PATENT INTERFERENCE PROCEEDINGS WITH SIENNA BIOPHARMACEUTICALS INC

BRIEF-Sienna Biopharmaceuticals Appoints John Smither As CFO

* SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER

BRIEF-Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56

* SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS

BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125

BRIEF-Sienna Biopharmaceuticals posts qtrly loss per share $1.12

* Sienna Biopharmaceuticals reports third quarter 2017 financial results

BRIEF-Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120

* Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120

BRIEF-Sienna Biopharmaceuticals reports Q2 loss of $6.50/shr

* Sienna Biopharmaceuticals reports second quarter 2017 financial results

BRIEF-Partner Fund reports 7.7 pct passive stake in Sienna Biopharmaceuticals

* Partner Fund Management LP reports 7.7 percent passive stake in Sienna Biopharmaceuticals Inc as of July 27, 2017 - SEC filing Source text: (http://bit.ly/2vfsuuL) Further company coverage:

BRIEF-Sienna Biopharmaceuticals shares open 27 pct above IPO price in debut

* Sienna Biopharmaceuticals Inc shares open at $19.05 in debut on the NASDAQ versus IPO price of $15.00

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up